Literature DB >> 24281994

Factors affecting sonographic preoperative local staging of endometrial cancer.

D Fischerova1, F Frühauf, M Zikan, I Pinkavova, R Kocián, P Dundr, K Nemejcova, L Dusek, D Cibula.   

Abstract

OBJECTIVES: To identify major factors in the under- and overestimation of cervical and myometrial invasion by endometrial cancer at preoperative staging by ultrasound.
METHODS: This prospective study involved all patients with histologically confirmed endometrial cancer referred consecutively for surgical staging between January 2009 and December 2011. All patients underwent transvaginal ultrasound examination, obtaining metric and perfusion data, and the results were compared with final histology: myometrial invasion was defined at histology in the final pathology report as being either < or ≥ 50%, while cervical stromal invasion was reported as being either present or absent, and sonographic over-/underestimation was determined relative to these.
RESULTS: Enrolled prospectively into the study were 210 patients. The proportion of cases with sonographic underestimation, relative to final histology, of myometrial invasion (i.e. false-negative estimation of no or superficial invasion < 50%) and of cervical invasion (i.e. false-negative finding of absence of stromal invasion) was comparable: 8.6% (n = 18) and 10.5% (n = 22), respectively. Myometrial invasion was overestimated by ultrasound (i.e. false-positive estimation of deep invasion ≥ 50%) in 15.7% (n = 33) of cases, and cervical invasion was overestimated (i.e. false-positive finding of presence of stromal invasion) in 4.8% (n = 10) of cases. These outcomes correspond to positive and negative predictive values of 67.6% (95% CI, 57.7-76.6) and 83.3% (95% CI, 74.9-89.8), respectively, for the subjective assessment of myometrial invasion, and 60.0% (95% CI, 38.2-79.2) and 88.1% (95% CI, 82.5-92.4), respectively, for that of cervical stromal invasion. The staging error in subjective assessment was not related to body mass index (BMI), to the position of the uterus in the pelvis or to image quality. Cervical and myometrial invasion were more often underestimated in well-differentiated endometrial cancers that were smaller in size, with thick minimum tumor-free myometrium and lower perfusion, and more often overestimated in moderately and poorly differentiated cancers that were larger in size, with thin minimum tumor-free myometrium and richer perfusion.
CONCLUSION: The accuracy of subjective assessment of myometrial and cervical invasion by ultrasound was significantly influenced by tumor size, density of tumor vascularization, tumor vessel architecture and histological grading, while it was not significantly affected by BMI, uterine position and image quality.
Copyright © 2013 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  FIGO staging; cervical stromal invasion; endometrial cancer; myometrial invasion; transvaginal sonography; ultrasound

Mesh:

Year:  2014        PMID: 24281994     DOI: 10.1002/uog.13248

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  12 in total

Review 1.  Ultrasound in gynecological cancer: is it time for re-evaluation of its uses?

Authors:  Daniela Fischerova; David Cibula
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

2.  Diagnostic accuracy and economic impact of three work-up strategies identifying risk groups in endometrial cancer, fully incorporating sentinel lymph node algorithm.

Authors:  A A Novelli; A Puppo; M Ceccaroni; E Olearo; G Monterossi; G Mantovani; S Pelligra; P L Olearo; F Fanfani; G Scambia
Journal:  Facts Views Vis Obgyn       Date:  2020-10-08

Review 3.  What Is the Best Preoperative Imaging for Endometrial Cancer?

Authors:  Ingfrid S Haldorsen; Helga B Salvesen
Journal:  Curr Oncol Rep       Date:  2016-04       Impact factor: 5.075

4.  The Diagnostic Accuracy of Ultrasound in Assessment of Myometrial Invasion in Endometrial Cancer: Subjective Assessment versus Objective Techniques.

Authors:  Filip Frühauf; Michal Zikan; Ivana Semeradova; Pavel Dundr; Kristyna Nemejcova; Ladislav Dusek; David Cibula; Daniela Fischerova
Journal:  Biomed Res Int       Date:  2017-07-24       Impact factor: 3.411

5.  Is Tumor-Free Distance an Independent Prognostic Factor for Early-Stage Endometrioid Endometrial Cancer?

Authors:  Tufan Oge; Duygu Kavak Comert; Yusuf Cakmak; Deniz Arık
Journal:  J Oncol       Date:  2020-04-14       Impact factor: 4.375

6.  Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma.

Authors:  Wilko Weichert; Melanie Boxberg; Moritz Jesinghaus; Katja Steiger; Fabian Stögbauer; Bernhard Haller; Andreas Kolk; Ulrich Straßen; Anja Pickhard; Markus Wirth; Miguel Silva; Jan Budczies; Aaron Becker von Rose; Björn Konukiewitz; Peer Kuhn; Konrad Klinghammer; Hendrik Dapper; Stefan Münch; Stephanie E Combs
Journal:  Br J Cancer       Date:  2020-01-15       Impact factor: 7.640

7.  A prospective comparison of the diagnostic accuracies of ultrasound and magnetic resonance imaging in preoperative staging of endometrial cancer.

Authors:  Michael Wong; Tejal Amin; Nikolaos Thanatsis; Joel Naftalin; Davor Jurkovic
Journal:  J Gynecol Oncol       Date:  2022-01-17       Impact factor: 4.401

Review 8.  The Complementary Role of Imaging and Tumor Biomarkerszzm321990in Gynecological Cancers: An Update of the Literature

Authors:  Emanuela Anastasi; Silvia Gigli; Laura Ballesio; Antonio Angeloni; Lucia Manganaro
Journal:  Asian Pac J Cancer Prev       Date:  2018-02-26

9.  Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer?

Authors:  Aneta Cymbaluk-Płoska; Paula Gargulińska; Michał Bulsa; Sebastian Kwiatkowski; Anita Chudecka-Głaz; Kaja Michalczyk
Journal:  Diagnostics (Basel)       Date:  2021-03-31

Review 10.  Preoperative assessment of endometrial cancer.

Authors:  Péter Török; Zoárd Krasznai; Szabolcs Molnár; Rudolf Lampé; Attila Jakab
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.